Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024141 (
systemic lupus erythematosus
)
44,322
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Seventy unselected patients with
systemic lupus erythematosus
(
SLE
) were studied to determine the prevalence of
cognitive impairment
and the association with other clinical variables. Twenty-five patients with rheumatoid arthritis (RA) and 23 healthy subjects were used as controls. All patients were evaluated with a battery of standardized neuropsychological tests to determine ability in 8 areas of cognitive function. Clinically overt neuropsychiatric (NP)
SLE
, cumulative disease manifestations and concurrent medications were documented. In patients with
SLE
, generalized disease activity was expressed using the
SLE
disease activity index.
Cognitive impairment
was identified in 15/70 (21%) patients with
SLE
, 1/25 (4%) patients with RA and in 1/23 (4%) healthy subjects (p = 0.042). The prevalence was higher in patients with active NP-
SLE
at the time of assessment (2/5, 40%) compared to patients with inactive NP-
SLE
(2/10, 20%) but was also increased in those patients who had never had known clinical NP-
SLE
(11/55, 20%). A history of serositis (p = 0.015), active
SLE
(p = 0.064) and corticosteroid use (p = 0.027) at the time of assessment were more common in patients with
cognitive impairment
. The results suggest that
cognitive impairment
is increased in patients with
SLE
. It may occur independently of clinically overt NP-
SLE
and is more common in patients with active disease who are receiving corticosteroids.
...
PMID:Cognitive impairment in patients with systemic lupus erythematosus. 159 78
A review of the literature regarding central nervous system side effects of the nonsteroidal anti-inflammatory drugs (NSAIDs) revealed three general categories: aseptic meningitis, psychosis, and
cognitive dysfunction
. Aseptic meningitis is found most commonly in patients with
lupus
treated with ibuprofen, but it should be considered in any patient with meningitis if the patient has used NSAIDs. Psychosis, although infrequently reported with NSAIDs, should be suspected in an elderly patient started on a regimen of indomethacin who acutely develops disorientation, paranoia, or hallucinations. Finally, there appears to be some potential for memory dysfunction and attention deficits in elderly patients treated with NSAIDs. Until further studies are available on the incidence and severity of these cognitive changes, physicians should use low doses of NSAIDs in the elderly and remain alert to the possibility of such adverse side effects.
...
PMID:Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. 206 81
The hypothesis that lymphocytotoxic antibodies are associated with neuropsychiatric involvement in
systemic lupus erythematosus
(NP-SLE) is re-evaluated in this study. In an unselected cohort of 98 women with
SLE
a cross-sectional study has been performed to analyse associations among standardised clinical, neurological, and neuropsychological assessments and lymphocytotoxic antibodies measured by microcytotoxicity assay. Fifty patients showed objective clinical evidence of continuing or past NP-
SLE
and 54 patients had
cognitive impairment
. In accordance with previous observations 44% (24/54) of the cognitively impaired group did not have clinically detectable evidence of NP-
SLE
. Although lymphocytotoxic antibodies were found to be only marginally more prevalent in those patients with a clinical diagnosis of NP-
SLE
than in those without (32% v 23%), these antibodies were significantly associated with
cognitive impairment
(chi 2 = 5.42; p less than 0.02). No association was detected between lymphocytotoxic antibodies and either overall systemic disease activity or other organ system involvement, suggesting that the association between lymphocytotoxic antibodies and
cognitive dysfunction
in
SLE
is specific.
...
PMID:Serum lymphocytotoxic antibodies and neurocognitive function in systemic lupus erythematosus. 233 7
To determine the significance of changes in serum antineuronal antibody levels in
systemic lupus erythematosus
, 9 patients who had a rise and 11 patients who had a fall in neuronal antibody titre over a mean duration of 2.1 years (range 0.25-5.2) were identified. These changes were examined in the light of concurrent changes in other serological variables, overall disease activity, neuropsychiatric disease and neuropsychological tests. Changes in antineuronal antibodies were frequently associated with concurrent changes in anti-DNA antibodies and overall disease activity. When neuropsychiatric disease or
cognitive dysfunction
were present, their course showed a close correlation with changes in antineuronal antibody levels. The results support the association between antineuronal antibodies and neuropsychiatric-
systemic lupus erythematosus
, but suggest that their measurement will provide useful information of disease status in only a subpopulation of patients.
...
PMID:The association between sequential changes in serum antineuronal antibodies and neuropsychiatric systemic lupus erythematosus. 260 89
Systemic lupus erythematosus
(
SLE
) is an autoimmune disease characterized by frequent neuropsychiatric (NP) manifestations. At least two different pathogenetic mechanisms have been proposed for NP-
SLE
, including vasculitis and antibodies against neuronal antigens, the latter as expressed by the presence of brain cross-reactive lymphocyte antibodies. We have previously reported a high prevalence of
cognitive dysfunction
in
SLE
which can remain subclinical and which cannot be accounted for on the basis of disease activity, general distress, or steroid medication. In the present study, we undertook the same extensive, standardized neuropsychological testing in 98 consecutive female
SLE
patients in order to evaluate central nervous system functioning in relation to serum lymphocyte antibodies which were measured at the time of neuropsychological testing by a microcytotoxicity test. A significant association was observed between the presence of serum lymphocytotoxic antibodies (LCA) and
cognitive impairment
in patients with
SLE
. The pattern of impairment which predominated in the LCA-positive patients involved deficits in anteriorly associated, primarily visuospatial functions. These findings support the hypothesis of localization of a particular antigen-antibody interaction in the brain in
SLE
, suggesting the existence of immunological control mechanisms for normal brain functioning.
...
PMID:Neuropsychological correlates of serum lymphocytotoxic antibodies in systemic lupus erythematosus. 324 55
We have examined cerebrospinal fluid (CSF) and serum from patients with Sjogren's syndrome (SS) and
systemic lupus erythematosus
(
SLE
) for evidence of activation of the terminal pathway of complement. Fluid phase terminal complement complexes (SC5b-9), quantitated by ELISA, were detected in the CSF of 14 of 16 patients with SS and focal central nervous system (CNS) disease. Five of six SS patients without focal CNS disease but with psychiatric disease or
cognitive dysfunction
had detectable CSF SC5b-9, whereas two other SS patients without focal CNS or neuropsychiatric disease had no detectable CSF SC5b-9. Six of seven patients with
SLE
or
SLE
overlap syndrome with CNS involvement had CSF SC5b-9, whereas two patients with
SLE
without CNS involvement had no CSF SC5b-9. A subset of SS and
SLE
patients with CNS disease had SC5b-9 detected in CSF but not in serum. SC5b-9 was generally absent from the CSF of patients with noninflammatory CNS diseases. These findings demonstrate intrathecal activation of terminal complement in patients with CNS SS or CNS
SLE
, and suggest a role for terminal complement activation in the pathophysiology of CNS involvement in both SS and
SLE
.
...
PMID:Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren's syndrome or systemic lupus erythematosus. 355 3
Eighty-six females with
systemic lupus erythematosus
(
SLE
) were grouped according to present or past history of neuropsychiatric (NP) symptomatology (Active, Inactive, or Never). Performance of these three groups was compared to that of 35 normal women on an extensive battery of neuropsychological tests sampling a wide range of cognitive functions. In addition to making group comparisons, we also devised a system for identifying individual impairment using decision rules for both quantitative and qualitative data. Our results indicate that a variety of cognitive deficits are present in
SLE
patients taken together as a group; there is no significant association between
cognitive impairment
and emotional disturbance; patients with resolved NP symptomatology are as impaired as patients with active NP symptoms, suggesting residual CNS involvement; in spite of no significant difference emerging on direct group comparisons, significantly more Never NP-
SLE
patients are impaired than are controls on several summary scores, suggesting subclinical CNS involvement in these patients.
...
PMID:Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. 359 26
We administered a battery of neuropsychological tests to 62 female patients with
systemic lupus erythematosus
(
SLE
), 12 female patients with rheumatoid arthritis (RA), and 35 normal control subjects. By applying objective decision rules to individual test protocols, an overall prevalence of
cognitive impairment
of 66% was obtained in the
SLE
patient sample. Independent clinical, radiological, and laboratory data were used to determine neuropsychiatric (NP) symptomatology and to group
SLE
patients as 1) "active" (N = 21), 2) "inactive" (N = 15), and 3) "never" (N = 26) NP-
SLE
. More than 80% of the patients in groups 1 and 2 and 42% in group 3 showed significant
cognitive impairment
as compared with 17% of the RA patients and 14% of the normal control subjects. Neither steroid medication nor psychological distress could account for these findings. The unexpectedly high prevalence of
cognitive impairment
in
SLE
patients with either inactive or absent neuropsychiatric symptomatology provides evidence for subclinical nervous system involvement in
SLE
.
...
PMID:Prevalence of cognitive impairment in systemic lupus erythematosus. 371 79
The pathogenesis of neuropsychiatric
lupus
(NP-
SLE
) is unclear, but may involve vasculopathy, antibodies against nervous system tissue, or both. A major difficulty in determining the significance of antineuronal antibodies in NP-
SLE
has been lack of consistent clinical diagnostic approaches. By utilizing a new clinical classification of NP-
SLE
, neuropsychological assessments, and an assay for IgG antineuronal antibodies, we have found a significant association between antibody-positivity and
cognitive impairment
or nonfocal NP-
SLE
. These observations indicate that antineuronal antibodies may play a role in NP-
SLE
and emphasize the clinical importance of cognitive function in patients with
SLE
.
...
PMID:Neuronal antibodies and cognitive function in systemic lupus erythematosus. 382 39
Hyperbaric oxygen has been used in patients with rheumatic disease for many years without reports of untoward or unusual complications for a variety of non-rheumatic indications. Recent evidence that hyperbaric oxygen inhibits the actions of certain cytokines, acts as an immune modulator and may help
cognitive dysfunction
has resulted in a re-examination of its potential role in rheumatic diseases. A case report of a
lupus
/scleroderma crossover patient is presented whose
cognitive dysfunction
improved after hyperbaric oxygen therapy. The history of hyperbaric oxygen and its physiology are related, along with a focused review of its effects on the immune and central nervous systems. Areas which might warrant further consideration by rheumatologists are outlined, as well as areas of concern.
Lupus
1995 Jun
PMID:Use of hyperbaric oxygen in rheumatic diseases: case report and critical analysis. 864 34
1
2
3
4
5
6
7
8
9
10
Next >>